A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (NCT04211337)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
🩺 Plain-English Summary (8th-Grade Level)
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (143 Sites)
Showing the first 25 of 143 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- City of Hope National Medical Center — Duarte, California
- UCLA Hematology/Oncology - Westwood (Building 100) — Los Angeles, California
- University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento, California
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance, California
- Emory University — Atlanta, Georgia
- University of Chicago Medical Center — Chicago, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Cincinnati Medical Center — Cincinnati, Ohio
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- University of Pennsylvania Hospital — Philadelphia, Pennsylvania
- Thomas Jefferson University — Philadelphia, Pennsylvania
- University of Texas MD Anderson Cancer Center — Houston, Texas
- University of Wisconsin Hospitals and Clinics — Madison, Wisconsin
- Royal North Shore Hospital — St Leonards, New South Wales
- The Alfred Hospital — Melbourne, Victoria
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- Sir Charles Gairdner Hospital — Perth, Western Australia
- Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman — Liège,
- Oncocentro — Belo Horizonte, Minas Gerais
- Hospital de Cancer de Londrina — Londrina, Paraná
- Hospital de Clinicas de Porto Alegre — Porto Alegre, Rio Grande do Sul
- Fundação Pio XII - Hospital de Câncer de Barretos — Barretos, São Paulo
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Medullary Thyroid Cancer
- A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer — St Leonards, New South Wales
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors — Los Angeles, California
- A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study — San Francisco, California
- Natural History Study of Children and Adults With Medullary Thyroid Cancer — Bethesda, Maryland
Explore by condition: All Medullary Thyroid Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.